COR — Cencora, Inc.

Cencora, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Diluted EPS: $4.08, up 9% year-over-year.
• Consolidated Revenue: $85.9 billion, a 5.5% increase.
• Consolidated Gross Profit: $3 billion, up 18%, with a gross profit margin of 3.48%.
• Operating Income: $1.1 billion, a 12% increase.
• Net Interest Expense: $72 million, up $44 million due to debt financing for acquisitions.
• Cash Balance: $1.8 billion, with negative adjusted free cash flow of $2.4 billion for the quarter.
• Share Count: 195.3 million shares, with a projected full-year diluted share count of approximately 105.5 million shares.

2. Strategic Updates and Business Highlights

• Acquisition of OneOncology: Completed acquisition of majority equity interest, enhancing Cencora's capabilities in community oncology.
• Growth Priorities: Focus on strengthening leadership in specialty pharmaceuticals, leading with market leaders, and enhancing patient access.
• MSO Expansion: Investments in Managed Service Organizations (MSOs) are expected to drive value through improved back-office support and clinical research capabilities.
• Performance in Segments:
  • US Healthcare Solutions: Revenue of $76.2 billion, up 5%, with strong growth in GLP-1 products and specialty sales.
  • International Healthcare Solutions: Revenue of $7.6 billion, up 10% (6% constant currency), though operating income declined due to timing of price adjustments.
  • Other Revenue: $2.1 billion, up 6%, driven by MWI Animal Health and ProPharma.

3. Forward Guidance and Outlook

• Adjusted EPS Guidance: Reaffirmed range of $17.45 to $17.75 for the fiscal year.
• Revenue Growth: Expected to be in the range of 7% to 9%, up from 5% to 7%.
• Operating Income Growth: Increased guidance to 11.5% to 13.5%, up from 8% to 10%.
• Interest Expense: Expected to be $480 million to $500 million, reflecting higher debt levels due to acquisitions.

4. Challenges and Points of Concern

• Customer Loss: Offboarding of a large grocery customer and loss of an oncology customer due to acquisition by a competitor are expected to impact revenue and operating income growth.
• International Segment Weakness: Decline in operating income attributed to timing issues with manufacturer price adjustments, although guidance remains unchanged for the fiscal year.
• Negative Free Cash Flow: Seasonal working capital needs resulted in negative adjusted free cash flow, although expected to improve over the fiscal year.

5. Notable Q&A Insights

• Operating Income Deceleration: Analysts expressed concerns about potential deceleration in operating income growth, particularly in the US segment, which management addressed by highlighting strong underlying performance despite challenging comparisons.
• MSO Contributions: Questions regarding the impact of MSO acquisitions on growth were met with confidence in leveraging clinical trial capabilities and revenue cycle management to drive future growth.
• Market Dynamics: Management noted no significant changes in drug pricing dynamics in Europe related to US policies, indicating stable business conditions.
• Divestiture Strategy: Discussions around potential divestitures emphasized a focus on growth-oriented investments, with management open to strategic alternatives for non-core businesses.

Overall, Cencora reported a strong start to fiscal 2026, driven by strategic acquisitions and solid performance in its US healthcare solutions segment, while also navigating challenges in customer retention and international operations.